Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European ...

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European ...

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 ...
TipRanks on MSN

Nurix Therapeutics Initiates DAYBreak Phase 2 Trial

On October 22, 2025, Nurix Therapeutics announced the initiation of the DAYBreak clinical trial, a pivotal Phase 2 study of bexobrutideg in patients with relapsed or refractory chronic lymphocytic ...
TipRanks on MSN

Nurix Therapeutics Announces $250M Stock Offering

The latest update is out from Nurix Therapeutics ( (NRIX) ).

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic ...
Science Daily

Breakthrough cancer therapy stops tumor growth without harming healthy cells

Scientists have found a new way to stop cancer growth without damaging healthy cells. Researchers from the Francis Crick ...